Side effects from early treatment of low and intermediate risk prostate cancer need to be balanced agains the new finding that mortality is no different during the first ten years irrespective of the
The large randomized Prostate Testing for Cancer and Treatment (ProtecT) study reported in two linked papers in the New England Journal of Medicine—has found that in low and intermediate risk disease radical prostatectomy and radiotherapy did not reduce prostate-specific or overall mortality after 10 years as compared with “active monitoring” but these treatments did reduce the spread of the disease. Jenny Donovan, Professor of Social Medicine at Bristol University, describes the trade-off needed between side effects such as a 90 percent risk of sexual dysfunction and 50 percent chance of urinary incontinence which now need to be weighed against the potential of reducing risks beyond ten years.
Related Episodes
Jelle Wesseling MD PhD; 2026 EBCC: ‘Lord’ Trial Finds Active Surveillance for Estrogen-Receptor-Positive, HER2- Negative, Grade 1–2 DCIS Just As Effective as Standard Therapy
At the 2026 EBCC, Jelle Wesseling MD PhD discusses the LORD-trial, which found active surveillance for low-risk, estrogen-receptor-positive, HER2-negative, grade 1–2 DCIS is as effective as standard therapy. The trial's reassuring findings led to early cessation of randomization, supporting de-escal
Erica L. Mayer MD MPH: Adjuvant Abemaciclib: Start Low, then Dose Escalate in Early-stage HR+/HER2- Breast Cancer: TRADE Study Findings
Interview with Erica L. Mayer MD MPH, Director of Breast Cancer Clinical Research, Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA. With comment from: Pat Price MD, Imperial College